Low Dose Theophylline and Tiotropium Rotacap as Add on Therapy in COPD Patients-Clinical Trial
DOI:
https://doi.org/10.51985/JBUMDC2020001Abstract
Objectives: To compare the role of low dose Theophylline and Tiotropium rotacap in improving the lung functions and
day to day life of patients suffering from COPD.
Study Design and Setting: A Clinical trial study was conducted at Department of Pharmacology and Therapeutics, BMSI
in association with Department of Chest Medicine, JPMC.
Methodology: This study was planned as an open label and parallel clinical trial study. A total of 168 patients of COPD
were selected for this study and only 161 patients completed the 3 months duration of the study. The enrolled patients were
grouped into 2, namely A and B. Tab. Theophylline 350 mg was given to Group A in two divided doses while Tiotropium
rotacap18μg through rotahaler was given to group B once a day.
Results: Mean FEV1 ± SD was improved by 0.04 ± 0.02 in Theophylline therapy group while by 0.07 ± 0.01 in the
Tiotropium therapy treated group and a significant difference between the changes in the two treatment groups was evident.
There was a percentage improvement in PEFR of 8.9 ± 5.8 in the Theophylline therapy treated group and of 13.2 ± 4.7 in
Tiotropium therapy treated group. When Tiotropium group was compared with Theophylline group for improvement in
percentage change in PEFR from day 0, a significant difference was evident between the two groups. There was a significant
improvement from day 0 in CAT score in Tiotropium treated groups versus Theophylline group after 3 months of therapy.
Conclusion: Tiotropium rotacap was more effective as compared to low dose Theophylline in improving pulmonary
functions and CAT score in patients with COPD.
References
World Health Report. Geneva: World Health Organization.
Available from URL: http://www.who.int/ respiratory/copd/en/
accessed at 25-8-2018.
Rizvi N. COPD is the leading cause of death. Pulse Intern
Fortnightly Med News Paper, 2010; 1-14.
Beran D, Zar HJ, Perrin C, Menezes AM, Burney P, Forum
of International Respiratory Societies working group c. Burden
of asthma and chronic obstructive pulmonary disease and
access to essential medicines in low-income and middleincome
countries. The Lancet Respiratory medicine 2015;
(2): 159-70.
Eisner MD,Anthonisen N,Coultas D,Kuenzli N,Perez-Padilla
R,Postma Det al. An Official American Thoracic Society
Public Policy Statement: Novel Risk Factors and the Global
Burden of Chronic Obstructive Pulmonary Disease. Am J
RespirCrit Care Med 2010; 182:693–718.
de los MonterosEMJ, Pena C, Soto Hurtado EJ, Jareno J,
Miravitles M. Variability of respiratory symptoms in severe
COPD. Arch Bronchoneumol 2012; 48:3-7.
National Heart, Lung and Blood Institute. Morbidity and
mortality 2012 chartbook on cardiovascular, lung and blood
diseases. Bethesda, Maryland: US Department of Health and
Human Services, Public Health Service, National institute of
Health. Available at:http://www.nhlbi.nih.gov/ files/docs/
research/2012_Chart Book_508. pdf; Accessed at 25-6-2015.
Zwar NA, Marks GB, Hermiz O, Middleton SS, Comino EJ,
Hasan I et al. Predictors of accuracy of diagnosis of chronic
obstructive pulmonary disease in general practice. Med J
Aust., 2011; 195:168-171.
Cazzola M, Page CP, Calzetta and Matera MG. Pharmacology
and Therapeutics of Bronchodilators. Pharmacological Reviews
; 64:450-504.
Kew KM, Mavergames C, Walters JA. Long-acting beta2-
agonists for chronic obstructive pulmonary disease. Cochrane
Database Syst Rev 2013; 10(10): CD010177.
Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ.
Indacaterol, a once-daily beta2-agonist, versus twice-daily
beta(2)-agonists or placebo for chronic obstructive pulmonary
disease. Cochrane Database Syst Rev 2015; 1: CD010139.
Melani AS. Long-acting muscarinic antagonists. Expert Rev
ClinPharmacol., 2015; 8(4):479-501.
Singh D,Papi A,Corradi M,Pavlišová I,Montagna I,Francisco
Cet al. Single inhaler triple therapy versus inhaled corticosteroid
plus long-acting beta2-agonist therapy for chronic obstructive
pulmonary disease (TRILOGY): a double-blind, parallel
group, randomised controlled trial. Lancet 2016; 388(10048):
-73.
Brusasca V. Reducing cholinergic constriction: the major
reversible mechanism in COPD. EurRespir Rev 2006; 15:32-
Oenema TA et al. Pro-inflammatory mechanisms of muscarinic
receptor stimulation in airway smooth muscle. Respir Res.,
; 11:130.
Belmonte KE. Cholinergic pathways in the lungs and
anticholinergic therapy for chronic obstructive pulmonary
disease. Proc Am ThoracSoc 2005; 2:297–304.
Barnes PJ. Theophylline for COPD. Thorax. 2006; 61:742–744.
Cosio MG, Saetta M, and Agusti A. Immunologic Aspects of
Chronic Obstructive Pulmonary Disease N Engl J Med 2009;
:2445-2454.
Barnes PJ, Agusti A. Low-dose theophylline enhances the
anti-inflammatory effects of steroids during exacerbations of
COPD. Thorax 2009; 64:424-429.
[Gold] Global Initiative for Chronic Obstructive Lung Disease.
Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease, Updated 2013.
Available at:http://www.goldcopd. com Accessed at 25-8-
Husebo G, Köll R, et al. CAT-score is a predictor for mortality
in COPD. European Respiratory Journal 2016 48: 3106.
Marwick JA, Caramori G, Casolari P, Mazzoni F, Kirkham
PA, Adcock IM, Chung KF, Papi A. A role for phosphoinositol
-kinase delta in the impairment of glucocorticoid
responsiveness in patients with chronic obstructive pulmonary
disease. J Allergy ClinImmunol. 2010; 125:1146-53.
Jones PW1, Brusselle G, Dal Negro RW, Ferrer M, Kardos
P, et al. Properties of the COPD assessment test in a crosssectional
European study. EurRespir J. 2011; 38(1):29-35.
To M, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, et al.
Targeting phosphoinositide-3-kinase-ä with theophylline
reverses corticosteroid insensitivity in COPD. Am J RespirCrit
Care Med. 2010; 182:897–904.Bellia V, Foresi A, Bianco S, Grassi V, Olivieri D, Bensi G
and Volonte M. Efficacy and safety of oxitropium bromide,
theophylline and their combination in COPD patients: a
double-blind, randomized, multicenter study (BREATHTrial).
Respir Med 2002; 96:881- 889.
Augusti A, Calverly PMA, Celli B, Coxson HO, Edwards
LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman
EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J.
Characterisation of COPD heterogeneity in the ECLIPSE
cohort. Respir Res 2010; 11:122.
Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ,
Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, et
al. Low-dose oral theophylline combined with inhaled
corticosteroids for people with chronic obstructive pulmonary
disease and high risk of exacerbations: a RCT. Health Technol
Assess. 2019 Jul; 23(37):1-146
Freeman D, Lee A, Price D. Efficacy and safety of tiotropium
in COPD patients in primary care– the SPiRiva Usual Care
(SPRUCE) study. Respir Res 2007; 8:45.
Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium
in chronic obstructive pulmonary disease. N Engl J Med 2008;
:1543-1554.
Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM,
Barnes PJ. Treatment effects of low-dose theophylline
combined with an inhaled corticosteroid in COPD. Chest.
; 137(6):1338-44.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Muzna Hameed Dar, Syed Mehboob Alam, Qurrat ul Ain Bukhari, Kauser Ismail, Syed Azhar Hussain Zaidi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
